Selected article for: "blood glucose and clinical trial"

Title: Research Communications of the 24th ECVIM-CA Congress
  • Document date: 2015_1_10
  • ID: r59usk02_181
    Snippet: The study was designed as a prospective, placebo-controlled clinical trial. Cats were randomly assigned to two groups receiving exenatide ER (group 1: Bydureon â , 200 mg/kg, q7d, SC) or 0.9% saline solution (group 2: q7d, SC). Both groups additionally received insulin glargine (Lantus â , initial dose: ≤ 4 kg: 1.0 IU, q12 h; > 4 kg 1.5-2.0 IU, q12 h) and diet (Purina DM â ). Exenatide ER was applied over 16 weeks or, in case of remission, f.....
    Document: The study was designed as a prospective, placebo-controlled clinical trial. Cats were randomly assigned to two groups receiving exenatide ER (group 1: Bydureon â , 200 mg/kg, q7d, SC) or 0.9% saline solution (group 2: q7d, SC). Both groups additionally received insulin glargine (Lantus â , initial dose: ≤ 4 kg: 1.0 IU, q12 h; > 4 kg 1.5-2.0 IU, q12 h) and diet (Purina DM â ). Exenatide ER was applied over 16 weeks or, in case of remission, for 4 additional weeks after cessation of insulin application. Cats were rechecked 1, 3, 6, 10 and 16 weeks after starting therapy. Remission of diabetes was defined as absence of clinical signs of diabetes and normal blood glucose and fructosamine concentrations for at least 4 weeks after discontinuing insulin injections.

    Search related documents:
    Co phrase search for related documents